Pfizer Q1 revenue rises 5% to $14.5 billion; adjusted EPS falls 18% to $0.75
Pfizer reported first-quarter 2026 revenue of $14.5 billion, up 5% from a year earlier (2% on an operational basis). Adjusted diluted EPS fell 18% to $0.75 and reported diluted EPS fell 10% to $0.47. The company reaffirmed its full-year 2026 guidance of $59.5 to $62.5 billion in revenue and $2.80 to $3.00 in adjusted diluted EPS, so shareholders get a steady outlook alongside lower first-quarter profit.
Key points
- Revenue was $14.5 billion, up 5% reported and 2% operationally; excluding Comirnaty and Paxlovid, revenue grew 7% operationally.
- Reported net income attributable to Pfizer shareholders was $2,687 million, down 9% from $2,967 million a year earlier.
- Full-year 2026 guidance was reaffirmed: revenue of $59.5 to $62.5 billion and adjusted diluted EPS of $2.80 to $3.00; guidance assumes no share repurchases in 2026.
- Pfizer paid $2.4 billion in cash dividends, or $0.43 per share, during the first three months of 2026.
The filing
Written by AI on Nov 8, 2026, 2:16 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 05, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.